NCT07025460View on ClinicalTrials.gov

Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

October 17, 2024

Study Completion Date

January 18, 2026

Conditions
Chronic Kidney Disease
Interventions
DRUG

darbepoetin alfa

Participants receive darbepoetin alfa administered subcutaneously once every 4 weeks for 12 weeks during the evaluation phase. Dose adjustments are made to maintain hemoglobin levels within 10.0-11.0 g/dL.

Trial Locations (1)

Unknown

Institutional Review Board, Gangnam Severance Hospitial Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Gangnam Severance Hospital

OTHER